PhotoPharmics
-
PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
351-patient trial completion marks a key milestone for the Celeste® program; topline data to be presented May 26…
-
PhotoPharmics Phase 2 Parkinson’s Disease
PhotoPharmics will be attending the American Academy of Neurology Annual Meeting (AAN) in Chicago, April 18-22.
-
PhotoPharmics Announces Publication of Phase 2 Clinical Trial Results in Neurotherapeutics and Its Role in the Company’s Phase 3/Pivotal Clinical Trial
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease
-
PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial
PhotoPharmics Surpasses Enrollment Target with 350 Participants in First-of-a-Kind Remote, Home-Based Phase 3 “Light for PD” Clinical Trial
-
PhotoPharmics to Feature Photo Neurostimulation at the 2025 Movement Disorders Society International Congress
Attendees invited to Booth #732 for pivotal trial updates and to discuss unmet needs in Parkinson’s care.
-
PhotoPharmics Forms Commercial Advisory Board to Guide Market Launch of Breakthrough Parkinson’s Therapy
Renowned leaders in neurology, movement disorders, and commercialization join to shape Celeste® market strategy
-
PhotoPharmics Closes Oversubscribed $6 Million Series B Extension to Advance FDA Breakthrough Parkinson’s Device
Funding supports key milestones as the Pivotal, Phase 3 trial surpasses 200 enrolled participants.
-
PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board
PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board
-
PhotoPharmics Enrolls First 25 Patients in Pivotal Parkinson’s Disease Study to Improve Symptoms Beyond the Current Standard of Care
Groundbreaking at-home pivotal trial of a much-anticipated therapeutic device is underway
-
PhotoPharmics Enrolls First 25 Patients in Pivotal Parkinson’s Disease Study to Improve Symptoms Beyond the Current Standard of Care
Groundbreaking at-home pivotal trial of a much-anticipated therapeutic device is underway.
-
PhotoPharmics Launches Largest Phototherapy Trial for Parkinson’s Disease
Pivotal Trial for Improving Overall Function and Quality of Life
-
Innovative Research, Inclusive Trials, and New Funding Drives Hope for People with Parkinson’s Disease
PhotoPharmics Secures $16 Million Investment Led by Kickstart to Fund Pivotal Clinical Trial for FDA Market Authorization
Call to Action
Post Category
- BioUtah COVID-19 Analysis
- BioUtah News
- Business Tools & Resources
- Call to Action
- chair
- COVID-19 Legislation
- COVID-19 Updates
- Economic Developments
- Events
- Events
- Feature
- Featured Members
- Federal News
- Funding
- Funding
- Guests Posts
- HHS/FDA & Other Regulatory
- HR
- Industry News
- Life Sciences Events
- Life Sciences Industry News
- Newsletters
- Non-chair
- Policy News
- Press Releases
- State News
- Utah's Life Sciences Companies
- Workplace Safety
Latest Posts
- Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
- Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
- BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
- PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
- AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
